NCT06987318 - A Study to Evaluate the Safety and Antiviral Activity of Two Human Monoclonal Antibodies (VRC07-523LS and PGT121.414.LS) During Analytic Treatment Interruption in Participants Living With HIV Who Initiated ART During Acute/Early HIV-1 Infection | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 15, 2025

Primary Completion Date

August 29, 2027

Study Completion Date

May 7, 2028

Conditions

HIV-1-infection

Interventions

BIOLOGICAL

VRC07-523LS

Administered by Intravenous (IV) infusion at Week 0 and 12 weeks later

BIOLOGICAL

PGT121.414.LS

Administered by IV infusion at Week 0

Trial Locations (13)

Barranco CRS, Lima

Penn Therapeutics CRS, Philadelphia

Alabama CRS, Birmingham

Ohio State University CRS, Columbus

Northwestern University CRS, Chicago

Houston Advancing Research Team CRS, Houston

University of Colorado Hospital CRS, Aurora

UCSD Antiviral Research Center CRS, San Diego

The Ponce de Leon Center CRS, Atlanta

Massachusetts General Hospital CRS (MGH CRS), Boston

Chapel Hill CRS, Chapel Hill

Instituto de Pesquisas em AIDS do Rio Grande do Sul - IPARGS CRS, Porto Alegre

Instituto de Pesquisa Clinica Evandro Chagas (IPEC) CRS, Rio de Janeiro